Suchankova P, Yan J, Schwandt ML, et al
In this regard, the GIP and GLP-1 agonist, tirzepatide, currently shows promising data derived from phase 2 and 3 clinical trials
To date, dulaglutide, semaglutide, and tirzepatide have been the three predominant GLP-1 therapeutics employed in the treatment of T2DM, and their applications have been broadened to include weight management
The brain contains IGF-1 receptors, and the growth factor plays roles in neural development and maintenance
In comparison with healthy sham hamster, PBS treatment to infected hamsters resulted in 3305 up-regulated genes and 3764 down-regulated genes, respectively (Fig
The full Certificate of Analysis is available below